CEO Miles White said, “The slowdown in China does not apply to drugs.”
3Q15 results were adversely affected by the strong US Dollar, but YoY sales growth in constant currency was a robust 11% (excluding the MYL divestiture), the same growth rate as in 2Q15 (#msg-115595349).
ABT tightened 2015 guidance for non-GAAP EPS to $2.14-2.16 (from old range of $2.10-2.10).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.